

Jonathan H Schatz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8063201/publications.pdf>

Version: 2024-02-01

68
papers

2,350
citations

393982

19
h-index

214527

47
g-index

68
all docs

68
docs citations

68
times ranked

4696
citing authors

#	ARTICLE	IF	CITATIONS
1	RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. <i>Nature</i> , 2014, 513, 65-70.	13.7	506
2	Graded Expression of Interferon Regulatory Factor-4 Coordinates Isotype Switching with Plasma Cell Differentiation. <i>Immunity</i> , 2006, 25, 225-236.	6.6	480
3	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014, 123, 1293-1296.	0.6	345
4	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. <i>Cell</i> , 2011, 147, 554-564.	13.5	151
5	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Experimental Medicine</i> , 2011, 208, 1799-1807.	4.2	103
6	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021, 138, 2828-2837.	0.6	65
7	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	61
8	T Cell-Activating Bispecific Antibodies in Cancer Therapy. <i>Journal of Immunology</i> , 2019, 203, 585-592.	0.4	55
9	Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with <i>In Vivo</i> Antitumor Activity. <i>Clinical Cancer Research</i> , 2018, 24, 4256-4270.	3.2	41
10	Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors. <i>Cancer Research</i> , 2015, 75, 2916-2927.	0.4	40
11	Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin's Lymphoma: Results, Biology, and Development Strategies. <i>Current Oncology Reports</i> , 2011, 13, 398-406.	1.8	38
12	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. <i>Journal of Experimental Medicine</i> , 2014, 211, 1379-1391.	4.2	32
13	A network of RNA-binding proteins controls translation efficiency to activate anaerobic metabolism. <i>Nature Communications</i> , 2020, 11, 2677.	5.8	32
14	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. <i>Blood</i> , 2022, 140, 491-503.	0.6	32
15	Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	30
16	Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. <i>American Journal of Hematology</i> , 2019, 94, 585-596.	2.0	25
17	Translational remodeling by RNA-binding proteins and noncoding RNAs. <i>Wiley Interdisciplinary Reviews RNA</i> , 2021, 12, e1647.	3.2	23
18	Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001719.	0.5	22

#	ARTICLE	IF	CITATIONS
19	ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4082-4085.	1.0	22
20	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	0.6	20
21	Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447. <i>Oncotarget</i> , 2016, 7, 63362-63373.	0.8	18
22	TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. <i>Oncotarget</i> , 2016, 7, 23715-23729.	0.8	17
23	Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 2922-2922.	0.6	15
24	Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translome. <i>Cell Reports</i> , 2021, 37, 109806.	2.9	15
25	Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study. <i>Oncology</i> , 2018, 94, 274-280.	0.9	14
26	Targeted cancer therapy. <i>Cell Cycle</i> , 2011, 10, 3830-3833.	1.3	13
27	NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. <i>Cancers</i> , 2021, 13, 639.	1.7	13
28	Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors. <i>Cancer Research</i> , 2021, 81, 763-775.	0.4	13
29	eIF4A inhibition: ready for primetime?. <i>Oncotarget</i> , 2018, 9, 35515-35516.	0.8	12
30	Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells. <i>Biomarkers in Cancer</i> , 2015, 7s2, BIC.S29326.	3.6	10
31	Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 58-64.	0.2	10
32	Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy. <i>Blood</i> , 2021, 138, 42-42.	0.6	10
33	The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. <i>Oncogene</i> , 2020, 39, 2103-2117.	2.6	9
34	A translational program that suppresses metabolism to shield the genome. <i>Nature Communications</i> , 2020, 11, 5755.	5.8	8
35	A Rare Presentation of In Situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2014, 2014, 1-7.	0.3	7
36	Jekyll and Hyde: Activating the Hypoxic Translational Machinery. <i>Trends in Biochemical Sciences</i> , 2021, 46, 171-174.	3.7	7

#	ARTICLE	IF	CITATIONS
37	Mouse models of cancer as biological filters for complex genomic data. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 701-704.	1.2	6
38	Potency Meets Precision in Nano-optimized Chemotherapeutics. <i>Trends in Biotechnology</i> , 2021, 39, 974-977.	4.9	6
39	Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15727-15746.	2.9	6
40	CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation. <i>Blood Advances</i> , 2019, 3, 1788-1794.	2.5	5
41	Progress against follicular lymphoma. <i>Current Opinion in Hematology</i> , 2013, 20, 320-326.	1.2	3
42	Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis. <i>Blood</i> , 2016, 128, 5973-5973.	0.6	3
43	Molecular Dynamics Simulations Identify Tractable Lead-like Phenyl-Piperazine Scaffolds as eIF4A1 ATP-competitive Inhibitors. <i>ACS Omega</i> , 2021, 6, 24432-24443.	1.6	2
44	Next-Generation Sequencing Suggests Complex, Heterogeneous Pathogenesis In Peripheral T-Cell Lymphoma Unspecified. <i>Blood</i> , 2013, 122, 843-843.	0.6	2
45	Central Nervous System Involvement by Small Lymphocytic Lymphoma after a Myxoma-Related Embolic Event. <i>Case Reports in Hematology</i> , 2019, 2019, 1-6.	0.3	1
46	Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cyto-reduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma (NHL): Interim Results Of a Phase II Study. <i>Blood</i> , 2013, 122, 4404-4404.	0.6	1
47	Inhibition of Mitochondrial Translation By the Marine Natural Product Elatol Shows Potent Antileukemia Activity. <i>Blood</i> , 2021, 138, 4342-4342.	0.6	1
48	Loss of IRF-4 Exacerbates the CML-Like Phenotype of IRF-8 Knockout Mice.. <i>Blood</i> , 2004, 104, 2952-2952.	0.6	0
49	IRF-4 Functions as a Myeloid Tumor Suppressor.. <i>Blood</i> , 2006, 108, 2206-2206.	0.6	0
50	Oncogenic Pim Kinase Activity Provides Resistance to Mtor Inhibition in Vitro and In Vivo.. <i>Blood</i> , 2009, 114, 3974-3974.	0.6	0
51	Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker In Lymphoma. <i>Blood</i> , 2010, 116, 119-119.	0.6	0
52	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Cell Biology</i> , 2011, 194, i9-i9.	2.3	0
53	MicroRNAs Mediate Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive B-ALL by Down-Regulating Key Tumor Suppressors. <i>Blood</i> , 2011, 118, 2553-2553.	0.6	0
54	Induced Dependence On The ALK Kinase Inhibitor Crizotinib In Formerly Sensitive Anaplastic Large Cell Lymphoma Cells. <i>Blood</i> , 2013, 122, 3842-3842.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom. Blood, 2013, 122, 1831-1831.	0.6	0
56	Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation. Blood, 2014, 124, 4496-4496.	0.6	0
57	Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1. Blood, 2014, 124, 506-506.	0.6	0
58	Kinase overexpressing cancers responsive to drug withdrawal. Aging, 2015, 7, 752-753.	1.4	0
59	Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 3969-3969.	0.6	0
60	Novel Therapy for Aggressive Cutaneous T-Cell Lymphoma Leading to Complete Clinical Remission before Allogenic Stem Cell Transplantation. Blood, 2018, 132, 5354-5354.	0.6	0
61	Computational Identification of Tractable Drug-like Inhibitors of eIF4A1. Blood, 2018, 132, 5802-5802.	0.6	0
62	CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients. Blood, 2018, 132, 779-779.	0.6	0
63	NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation. Blood, 2019, 134, 2796-2796.	0.6	0
64	Identification of Tractable Drug-like eIF4A1 Inhibitors with Potent Anti-Tumor Activity. Blood, 2019, 134, 5760-5760.	0.6	0
65	Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics. Blood, 2019, 134, 4061-4061.	0.6	0
66	PI3K/AKT Activation Mediates B-Cell Transformation By the "T" Splice-Variant of Fyn Kinase. Blood, 2021, 138, 4334-4334.	0.6	0
67	R-Nanochop Incorporating a TFR1-Targeted Doxorubicin Nanocarrier Is Superior to R-CHOP in a PDX Model of Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 43-43.	0.6	0
68	Is There an Unequal Benefit of Autologous Stem Cell Transplant in Different Cytogenetic Groups of High Risk Patients with Multiple Myeloma: The University of Miami Experience. Blood, 2020, 136, 42-43.	0.6	0